Option chain shows key data for Psyence Biomedical's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Psyence Biomedical.

Psyence Biomedical (NASDAQ:PBM) Stock, Option Chain

Psyence Biomedical

Psyence Biomedical Ltd is a life science biotechnology company pioneering the use of natural psychedelics in mental health and wellbeing. It develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The company has commenced the clinical trial process to evaluate the safety and efficacy of its product candidates. It cultivates natural psilocybin mushrooms at its federally licensed facility in Southern Africa. This product is produced for export to its partners across the world to be processed into a standardized encapsulated product.

2-2-2

Cannabis

News

Psychedelics

Press Releases

OPTHF

Psyence Biomed launches Phase IIb trials for psilocybin in palliative care and Alcohol Use Disorder, bolstering its clinical pipeline with key acquisitions and partnerships.

Psychedelic Biotech Psyence Grows Pipeline With Trials And Psilocybin Drug Developer Acquisition

movers image

Pre-Market Outlook

Markets

Movers

Trading Ideas

ADAG

ATPC

DRMA

EGIO

ENTO

IOBT

ITOS

LDTC

NCNA

PPBT

PTIX

SQFT

TNON

XCUR

Why Exicure Shares Are Trading Higher By Over 49%; Here Are 20 Stocks Moving Premarket

Psyence Biomed initiates a Phase IIb psilocybin trial in Australia to explore its potential as a treatment for Adjustment Disorder.

Psyence Biomed Launches First Trial Site In Australia For Phase IIb Psilocybin Study In Palliative Care

Psyence Biomedical Ltd. - Ordinary Shares

Psyence Biomedical Ltd

PACIFIC BAY MINERALS LTD by Pacific Bay Minerals Ltd.

Pacific Bay Minerals Ltd

PACIFIC BOOKER MINERALS by Pacific Booker Minerals Inc.

Pacific Booker Minerals Inc

PGIM US Large-Cap Buffer 20 ETF - March

PT BUMI RESOURCES TBK by PT Bumi Resources TBK

PT Bumi Resources Tbk

PT BUMI RESTBK UNSP/ADR by PT Bumi Resources TBK

SHL Telemedicine Ltd PGIM US Large-Cap Buffer 20 ETF - May

<h3>Gainers</h3>
<ul>
<li>Mersana Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRSN#NASDAQ">MRSN</a>) shares rose 22.7% to $2.7 during Wednesday's pre-market session. The market value of their outstanding shares is at $331.2 million. As per the news, the Q3 earnings report came out today. </li>
<li>Kairos Pharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/KAPA#AMEX">KAPA</a>) stock rose 19.74% to $2.46. The market value of their outstanding shares is at $31.5 million. </li>
<li>Calidi Biotherapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CLDI#AMEX">CLDI</a>) shares increased by 18.48% to $2.5. The market value of their outstanding shares is at $29.1 million. The company's, Q3 earnings came out yesterday. </li>
<li>Natera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>) shares rose 16.66% to $157.64. The company's market cap stands at $19.4 billion. As per the news, the Q3 earnings report came out yesterday. </li>
<li>Ensysce Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSC#NASDAQ">ENSC</a>) stock increased by 15.62% to $0.78. The market value of their outstanding shares is at $11.6 million. The company's, Q3 earnings came out yesterday. </li>
<li>Lexeo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LXEO#NASDAQ">LXEO</a>) stock increased by 12.61% to $8.66. The company's market cap stands at $286.3 million. The company's, Q3 earnings came out today. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Syros Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYRS#NASDAQ">SYRS</a>) shares decreased by 85.6% to $0.39 during Wednesday's pre-market session. The market value of their outstanding shares is at $10.5 million. </li>
<li>GlucoTrack (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCTK#NASDAQ">GCTK</a>) stock decreased by 72.24% to $0.44. The market value of their outstanding shares is at $2.5 million. </li>
<li>Psyence Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) stock fell 23.4% to $0.05. The company's market cap stands at $2.9 million. </li>
<li>CERo Therapeutics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERO#NASDAQ">CERO</a>) shares declined by 20.03% to $0.21. The market value of their outstanding shares is at $32.1 million. </li>
<li>Geovax Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOVX#NASDAQ">GOVX</a>) shares declined by 20.0% to $2.6. The company's market cap stands at $22.1 million. As per the press release, Q3 earnings came out yesterday. </li>
<li>Virpax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRPX#NASDAQ">VRPX</a>) shares fell 17.6% to $0.51. The market value of their outstanding shares is at $2.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CERO

CLDI

ENSC

GCTK

GOVX

KAPA

LXEO

MRSN

NTRA

SYRS

VRPX

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Celularity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELU#NASDAQ">CELU</a>) shares moved upwards by 36.8% to $1.98 during Thursday's regular session. The market value of their outstanding shares is at $43.6 million. As per the news, the Q2 earnings report came out today. </li>
<li>Coherus BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRS#NASDAQ">CHRS</a>) shares moved upwards by 31.25% to $0.95. The market value of their outstanding shares is at $109.4 million. As per the press release, Q3 earnings came out yesterday. </li>
<li>Emergent BioSolutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>) shares increased by 30.76% to $12.03. The market value of their outstanding shares is at $630.3 million. As per the news, the Q3 earnings report came out yesterday. </li>
<li>Ensysce Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSC#NASDAQ">ENSC</a>) stock increased by 29.17% to $0.71. The market value of their outstanding shares is at $10.6 million. </li>
<li>Psyence Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) stock rose 23.03% to $0.08. The market value of their outstanding shares is at $4.0 million. </li>
<li>Myomo (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MYO#AMEX">MYO</a>) shares rose 19.61% to $5.0. The company's market cap stands at $151.1 million. As per the press release, Q3 earnings came out yesterday. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Xilio Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XLO#NASDAQ">XLO</a>) shares fell 28.7% to $0.92 during Thursday's regular session. The company's market cap stands at $40.4 million. </li>
<li>Dentsply Sirona (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XRAY#NASDAQ">XRAY</a>) shares fell 24.69% to $18.06. The company's market cap stands at $3.6 billion. As per the news, the Q3 earnings report came out today. </li>
<li>Personalis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSNL#NASDAQ">PSNL</a>) shares declined by 19.54% to $4.49. The market value of their outstanding shares is at $296.0 million. As per the news, the Q3 earnings report came out yesterday. </li>
<li>Axogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXGN#NASDAQ">AXGN</a>) shares decreased by 17.75% to $12.61. The company's market cap stands at $552.6 million. The company's, Q3 earnings came out today. </li>
<li>Harvard Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HBIO#NASDAQ">HBIO</a>) shares fell 17.56% to $2.33. The market value of their outstanding shares is at $101.3 million. As per the press release, Q3 earnings came out today. </li>
<li>Clover Health Investments (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLOV#NASDAQ">CLOV</a>) shares decreased by 16.41% to $3.64. The market value of their outstanding shares is at $1.8 billion. As per the press release, Q3 earnings came out yesterday. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AXGN

CELU

CHRS

CLOV

HBIO

PSNL

XRAY

12 Health Care Stocks Moving In Thursday's Intraday Session

<h3>Gainers</h3>
<ul>
<li>Recursion Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXRX#NASDAQ">RXRX</a>) stock moved upwards by 4181.6% to $274.02 during Monday's pre-market session. The market value of their outstanding shares is at $79.8 billion. </li>
<li>CVRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVRX#NASDAQ">CVRX</a>) stock increased by 8.88% to $14.59. The company's market cap stands at $316.7 million. As per the press release, Q3 earnings came out 4 days ago. </li>
<li>RAPT Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RAPT#NASDAQ">RAPT</a>) shares moved upwards by 8.07% to $2.41. The market value of their outstanding shares is at $84.1 million. </li>
<li>Palatin Techs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PTN#AMEX">PTN</a>) stock rose 5.0% to $1.26. The company's market cap stands at $24.6 million. </li>
<li>Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>) shares moved upwards by 4.87% to $1.29. The market value of their outstanding shares is at $237.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Venus Concept (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERO#NASDAQ">VERO</a>) stock fell 14.9% to $0.37 during Monday's pre-market session. The company's market cap stands at $2.6 million. </li>
<li>TG Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TGTX#NASDAQ">TGTX</a>) stock declined by 13.02% to $23.4. The market value of their outstanding shares is at $3.6 billion. As per the press release, Q3 earnings came out today. </li>
<li>Psyence Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) stock declined by 7.64% to $0.06. The market value of their outstanding shares is at $3.4 million. </li>
<li>Tharimmune (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THAR#NASDAQ">THAR</a>) stock declined by 6.7% to $2.51. The company's market cap stands at $2.8 million. </li>
<li>Verrica Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRCA#NASDAQ">VRCA</a>) stock declined by 5.23% to $1.45. The company's market cap stands at $61.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CVRX

NKTR

RAPT

RXRX

TGTX

THAR

VERO

VRCA

10 Health Care Stocks Moving In Monday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Nuwellis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUWE#NASDAQ">NUWE</a>) shares increased by 106.6% to $2.81 during Friday's after-market session. The company's market cap stands at $5.2 million. </li>
<li>Purple Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PPBT#NASDAQ">PPBT</a>) shares rose 8.36% to $3.37. The company's market cap stands at $114.2 million. </li>
<li>Kindly MD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KDLY#NASDAQ">KDLY</a>) stock moved upwards by 6.25% to $1.02. The company's market cap stands at $6.0 million. </li>
<li>SINTX Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SINT#NASDAQ">SINT</a>) stock increased by 6.18% to $3.26. The market value of their outstanding shares is at $2.4 million. </li>
<li>Omega Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMGA#NASDAQ">OMGA</a>) stock increased by 5.45% to $1.16. The market value of their outstanding shares is at $63.9 million. </li>
<li>Biomerica (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRA#NASDAQ">BMRA</a>) stock moved upwards by 5.0% to $0.39. The market value of their outstanding shares is at $6.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Psyence Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) shares declined by 10.1% to $0.06 during Friday's after-market session. The market value of their outstanding shares is at $3.3 million. </li>
<li>Venus Concept (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERO#NASDAQ">VERO</a>) stock fell 10.07% to $0.39. The market value of their outstanding shares is at $2.8 million. </li>
<li>Soligenix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNGX#NASDAQ">SNGX</a>) shares fell 6.96% to $3.56. The company's market cap stands at $8.1 million. </li>
<li>Envoy Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COCH#NASDAQ">COCH</a>) stock declined by 6.67% to $2.38. The market value of their outstanding shares is at $46.9 million. </li>
<li>Vaccinex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCNX#NASDAQ">VCNX</a>) shares declined by 6.11% to $2.77. The market value of their outstanding shares is at $7.7 million. </li>
<li>Fresh2 Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRES#NASDAQ">FRES</a>) stock decreased by 5.13% to $1.85. The company's market cap stands at $45.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BMRA

Envoy Medical, Inc. - Class A Common Stock

COCH

FRES

KDLY

NUWE

OMGA

SINT

SNGX

VCNX

12 Health Care Stocks Moving In Friday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Biofrontera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BFRI#NASDAQ">BFRI</a>) stock increased by 88.0% to $1.76 during Thursday's regular session. The company's market cap stands at $9.7 million. </li>
<li>Autonomix Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMIX#NASDAQ">AMIX</a>) stock increased by 27.24% to $13.03. The market value of their outstanding shares is at $15.0 million. </li>
<li>Anavex Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVXL#NASDAQ">AVXL</a>) stock increased by 22.59% to $7.0. The market value of their outstanding shares is at $593.5 million. </li>
<li>Aerovate Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVTE#NASDAQ">AVTE</a>) stock rose 22.32% to $2.68. The company's market cap stands at $77.3 million. </li>
<li>MiMedx Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDXG#NASDAQ">MDXG</a>) shares moved upwards by 22.05% to $6.95. The company's market cap stands at $1.0 billion. As per the news, the Q3 earnings report came out yesterday. </li>
<li>Exicure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XCUR#NASDAQ">XCUR</a>) stock rose 19.08% to $3.12. The market value of their outstanding shares is at $6.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Matinas BioPharma Hldgs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MTNB#AMEX">MTNB</a>) stock decreased by 69.1% to $0.6 during Thursday's regular session. The market value of their outstanding shares is at $2.9 million. </li>
<li>Anika Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANIK#NASDAQ">ANIK</a>) stock decreased by 28.39% to $17.68. The company's market cap stands at $257.8 million. The company's, Q3 earnings came out today. </li>
<li>Psyence Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) shares fell 24.95% to $0.07. The company's market cap stands at $3.8 million. </li>
<li>CalciMedica (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CALC#NASDAQ">CALC</a>) stock declined by 24.2% to $3.64. The market value of their outstanding shares is at $39.1 million. </li>
<li>Compass Pathways (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMPS#NASDAQ">CMPS</a>) shares fell 23.13% to $4.76. The company's market cap stands at $325.4 million. As per the news, the Q3 earnings report came out today. </li>
<li>Vaccinex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCNX#NASDAQ">VCNX</a>) stock fell 21.34% to $3.17. The company's market cap stands at $8.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AMIX

ANIK

AVTE

AVXL

BFRI

CALC

CMPS

MDXG

MTNB

<h3>Gainers</h3>
<ul>
<li>Autonomix Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMIX#NASDAQ">AMIX</a>) stock increased by 50.8% to $15.44 during Thursday's pre-market session. The company's market cap stands at $17.7 million. </li>
<li>Tenon Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNON#NASDAQ">TNON</a>) shares rose 34.96% to $4.4. The company's market cap stands at $2.4 million. </li>
<li>Aerovate Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVTE#NASDAQ">AVTE</a>) shares increased by 25.56% to $2.75. The company's market cap stands at $79.3 million. </li>
<li>Alphatec Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATEC#NASDAQ">ATEC</a>) stock increased by 24.73% to $7.01. The market value of their outstanding shares is at $984.6 million. The company's, Q3 earnings came out yesterday. </li>
<li>Envista Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVST#NYSE">NVST</a>) stock increased by 14.4% to $22.0. The company's market cap stands at $3.7 billion. As per the news, the Q3 earnings report came out yesterday. </li>
<li>Madrigal Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDGL#NASDAQ">MDGL</a>) shares increased by 13.46% to $245.0. The market value of their outstanding shares is at $5.3 billion. As per the news, the Q3 earnings report came out today. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Matinas BioPharma Hldgs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MTNB#AMEX">MTNB</a>) stock fell 51.8% to $0.93 during Thursday's pre-market session. The company's market cap stands at $4.6 million. </li>
<li>Equillium (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EQ#NASDAQ">EQ</a>) shares fell 42.76% to $0.79. The company's market cap stands at $27.9 million. </li>
<li>Ensysce Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSC#NASDAQ">ENSC</a>) shares decreased by 21.34% to $0.5. The market value of their outstanding shares is at $7.4 million. </li>
<li>CalciMedica (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CALC#NASDAQ">CALC</a>) shares decreased by 19.8% to $3.85. The company's market cap stands at $41.3 million. </li>
<li>Psyence Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) shares decreased by 19.15% to $0.08. The market value of their outstanding shares is at $4.1 million. </li>
<li>Compass Pathways (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMPS#NASDAQ">CMPS</a>) stock decreased by 16.81% to $5.15. The market value of their outstanding shares is at $352.1 million. The company's, Q3 earnings came out today. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ATEC

MDGL

NVST

12 Health Care Stocks Moving In Thursday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Autonomix Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMIX#NASDAQ">AMIX</a>) shares moved upwards by 50.8% to $15.44 during Thursday's pre-market session. The company's market cap stands at $17.7 million. </li>
<li>Tenon Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNON#NASDAQ">TNON</a>) shares moved upwards by 34.96% to $4.4. The company's market cap stands at $2.4 million. </li>
<li>Aerovate Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVTE#NASDAQ">AVTE</a>) shares rose 25.56% to $2.75. The market value of their outstanding shares is at $79.3 million. </li>
<li>Alphatec Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATEC#NASDAQ">ATEC</a>) shares increased by 24.73% to $7.01. The market value of their outstanding shares is at $984.6 million. As per the press release, Q3 earnings came out yesterday. </li>
<li>Envista Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVST#NYSE">NVST</a>) stock increased by 14.4% to $22.0. The company's market cap stands at $3.7 billion. As per the press release, Q3 earnings came out yesterday. </li>
<li>Madrigal Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDGL#NASDAQ">MDGL</a>) shares moved upwards by 13.46% to $245.0. The market value of their outstanding shares is at $5.3 billion. The company's, Q3 earnings came out today. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Matinas BioPharma Hldgs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MTNB#AMEX">MTNB</a>) shares fell 51.8% to $0.93 during Thursday's pre-market session. The market value of their outstanding shares is at $4.6 million. </li>
<li>Equillium (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EQ#NASDAQ">EQ</a>) stock decreased by 42.76% to $0.79. The market value of their outstanding shares is at $27.9 million. </li>
<li>Ensysce Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSC#NASDAQ">ENSC</a>) shares decreased by 21.34% to $0.5. The market value of their outstanding shares is at $7.4 million. </li>
<li>CalciMedica (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CALC#NASDAQ">CALC</a>) stock declined by 19.8% to $3.85. The company's market cap stands at $41.3 million. </li>
<li>Psyence Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) shares declined by 19.15% to $0.08. The market value of their outstanding shares is at $4.1 million. </li>
<li>Compass Pathways (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMPS#NASDAQ">CMPS</a>) shares fell 16.81% to $5.15. The market value of their outstanding shares is at $352.1 million. As per the news, the Q3 earnings report came out today. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

WIIM

Psyence Biomedical shares are trading higher after the company announced the recruitment of its Australia-based Empax Center as the second trial site for Psyence's Biomed ongoing Phase IIb clinical trial of nature-derived psilocybin as a potential treatment for Adjustment Disorder in Palliative Care.

Empax Center brings significant expertise in clinical trial execution for mental health and neurological conditions
Psyence Biomed on track to begin recruitment this quarter, and to announce Adjustment Disorder topline data in the second half of 2025

Biotech

General

Psyence Biomedical Announces Recruitment Of Second Clinical Trial Site For Ongoing Phase IIb Clinical Trial Of Nature-Derived Psilocybin For Adjustment Disorder In Palliative Care

Health Care

Psyence Biomedical Has Selected Empax Center As The Second Trial Site For The Company's Ongoing Phase 2b Trial Of Nature-derived Psilocybin As A Potential Treatment For Adjustment Disorder In Palliative Care

Following the successful export of its psilocybin extract to its CDMO in the UK, PsyLabs has now entered phase two of its development process.
The CDMO has commenced work on upscaling the purification process to validate its commercial viability, ensuring that the extraction methodology developed by PsyLabs can be efficiently scaled for larger production volumes.
This critical phase will confirm that the methods used to achieve PsyLabs&#39; high-purity psilocybin can be replicated on a commercial scale, setting the foundation for E.U. GMP certification.

Psyence Biomedical Says It Remains Confident That PsyLabs Is On Track To Produce GMP Certified, Nature-derived Psychedelic APIs

<h3>Gainers</h3>
<ul>
<li>Nuwellis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUWE#NASDAQ">NUWE</a>) stock moved upwards by 55.3% to $1.91 during Wednesday's regular session. The company's market cap stands at $3.5 million. </li>
<li>Streamline Health Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STRM#NASDAQ">STRM</a>) stock rose 24.54% to $2.74. The company's market cap stands at $11.5 million. </li>
<li>Inhibikase Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IKT#NASDAQ">IKT</a>) shares moved upwards by 22.68% to $1.46. The market value of their outstanding shares is at $10.8 million. </li>
<li>Kezar Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KZR#NASDAQ">KZR</a>) stock moved upwards by 18.28% to $0.88. The company's market cap stands at $63.8 million. </li>
<li>Shattuck Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STTK#NASDAQ">STTK</a>) shares rose 15.88% to $1.46. The company's market cap stands at $69.6 million. </li>
<li>CASI Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CASI#NASDAQ">CASI</a>) stock moved upwards by 15.78% to $6.6. The market value of their outstanding shares is at $102.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Windtree Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WINT#NASDAQ">WINT</a>) stock decreased by 22.0% to $0.72 during Wednesday's regular session. The company's market cap stands at $1.1 million. </li>
<li>Ontrak (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OTRK#NASDAQ">OTRK</a>) shares declined by 21.52% to $2.17. The company's market cap stands at $6.9 million. </li>
<li>AEON Biopharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AEON#AMEX">AEON</a>) stock fell 16.32% to $1.21. The market value of their outstanding shares is at $47.6 million. </li>
<li>Regional Health Props (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/RHE#AMEX">RHE</a>) stock decreased by 14.09% to $2.13. The market value of their outstanding shares is at $4.0 million. </li>
<li>Tivic Health Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIVC#NASDAQ">TIVC</a>) stock decreased by 13.64% to $0.23. The company's market cap stands at $1.3 million. </li>
<li>Psyence Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) stock declined by 11.72% to $0.1. The company's market cap stands at $1.5 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AEON

CASI

OTRK

STRM

STTK

TIVC

WINT

12 Health Care Stocks Moving In Wednesday's Intraday Session

Psyence Biomedical Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) ("Psyence Biomed" or the "Company"), a developer of psilocybin-based therapeutics, today provided an update on its previously announced proposed acquisition of Clairvoyant Therapeutics, Inc. Following the completion of necessary due diligence and other pre-closing activities specified in the conditional binding term sheet that was announced on September 9, 2024, Psyence Biomed has decided not to proceed with the acquisition at this time.
Psyence Biomed continues to advance its recently initiated Phase IIb clinical trial of nature derived psilocybin in conjunction with psychotherapy as a potential treatment for Adjustment Disorder following a life-limiting cancer diagnosis in Palliative Care. The first patient is expected to be randomized into the study this quarter, and topline data from the study is anticipated in the second half of 2025.
 &nbsp;

Contracts

Psyence Biomed Announces It Has Decided Not To Proceed With The Acquisition Of Clairvoyant At This Time

Asset Sales

Psyence Group Enters Agreement To Sell 11.13% Stake In Psylabs

Per the terms of the Proposed Acquisition, Psyence Biomed will issue to Psyence Group shares of its common stock valued at&nbsp;$1.1 million&nbsp;dollars, at a price of&nbsp;$0.55&nbsp;per share, in exchange for Psyence Group&#39;s&nbsp;11.13%&nbsp;stake in PsyLabs.

Psyence Biomedical Enters Agreement With Psyence Group For Acquisition Of 11.13% Stake In Privately-held PsyLabs For About $1.1M

Psyence Biomedical Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>), a biotechnology company focused on creating natural psychedelic-based solutions to address mental health challenges, has issued an <a href="https://www.globenewswire.com/news-release/2024/09/16/2946540/0/en/Psyence-Biomed-Issues-Shareholder-Update-Recapping-Recent-Progress-and-Previewing-Key-Upcoming-Data-Milestones.html">update</a> to shareholders, highlighting significant recent developments and upcoming milestones. 
The company has initiated a <a href="https://www.benzinga.com/markets/cannabis/24/09/40783399/psyence-biomed-launches-first-trial-site-in-australia-for-phase-iib-psilocybin-study-in-palliati">Phase IIb clinical trial in Australia</a> to evaluate psilocybin-assisted therapy for Adjustment Disorder in palliative care. Results are expected in late 2025, with hopes to advance to a Phase III trial thereafter. Psyence also strengthened its clinical supply chain by partnering with Optimi Health (OTC:<a class="ticker" href="https://www.benzinga.com/stock/OPTHF#OTC">OPTHF</a>) for GMP psilocybin extracts.
In addition to its palliative care program, Psyence expanded its pipeline into Substance Use Disorders, specifically Alcohol Use Disorder (AUD), through an exclusive licensing agreement with Psylabs. 
The company also announced the acquisition of Clairvoyant, a synthetic psilocybin drug developer, enhancing Psyence's AUD development efforts with data expected in early 2025.
These initiatives position Psyence for two critical data readouts in 2025, potentially paving the way for commercial success. Psyence also emphasized its strengthened financial position to support these ventures. CEO Dr. Neil Maresky expressed optimism about Psyence&#8217;s progress in developing <a href="https://www.benzinga.com/topic/psychedelic-assisted-therapies">psychedelic-based therapies</a> for mental health.
Cover image made with AI

<a href="https://www.globenewswire.com/en/news-release/2024/09/16/2946746/0/en/Psyence-Group-s-NASDAQ-Listed-Associate-Psyence-Biomedical-Announces-Initiation-of-First-Trial-Site-in-Australia-for-its-Phase-IIb-Study-of-Nature-Derived-Psilocybin-as-a-Potential.html" title="https://www.globenewswire.com/en/news-release/2024/09/16/2946746/0/en/Psyence-Group-s-NASDAQ-Listed-Associate-Psyence-Biomedical-Announces-Initiation-of-First-Trial-Site-in-Australia-for-its-Phase-IIb-Study-of-Nature-Derived-Psilocybin-as-a-Potential.html">https://www.globenewswire.com/en/news-release/2024/09/16/2946746/0/en/Psyence-Group-s-NASDAQ-Listed-Associate-Psyence-Biomedical-Announces-Initiation-of-First-Trial-Site-in-Australia-for-its-Phase-IIb-Study-of-Nature-Derived-Psilocybin-as-a-Potential.html</a>

Psyence Biomedical Announces Initiation Of First Trial Site In Australia For Phase IIb Study Of Nature Derived Psilocybin As Potential Treatment For Adjustment Disorder In Palliative Care

Shares of Exicure, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XCUR#NASDAQ">XCUR</a>) rose sharply in today's pre-market trading after the company entered into debt-for-equity exchange agreements and <a href="https://www.benzinga.com/quote/XCUR/news">regained Nasdaq compliance.</a>
Exicure shares jumped 49.3% to $2.39 in the pre-market trading.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>NuCana plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNA#NASDAQ">NCNA</a>) gained 94.4% to $4.94 in pre-market trading. NuCana presented final data from Phase 2 Nutide:701 study at ESMO Congress on NUC-7738 in combination with pembrolizumab for patients with metastatic melanoma who were refractory to or had relapsed on prior PD-1 inhibitor therapy.</li>
<li>Dermata Therapeutics, Inc.. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRMA#NASDAQ">DRMA</a>) rose 73.4% to $2.74 in today's pre-market trading after gaining around 7% on Tuesday.</li>
<li>Agape ATP Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATPC#NASDAQ">ATPC</a>) gained 53.1% to $2.68 in the pre-market trading session. Agape ATP shares jumped over 20% on Friday after the company announced it entered into a strategic collaboration with Xiamen Photons Solar Technology that focusing on developing solar photovoltaic mounting systems in ASEAN countries.</li>
<li>Tenon Medical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNON#NASDAQ">TNON</a>) gained 22.1% to $9.22 in pre-market trading after jumping around 72% on Friday. The company announced the pricing of a $4.5 million public offering of 1.22 million shares and warrants.</li>
<li>iTeos Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITOS#NASDAQ">ITOS</a>) rose 20.1% to $20.05 in pre-market trading. iTeos Therapeutics announced follow-up interim data from GALAXIES Lung-201 Phase 2 platform study sponsored by GSK, for Belrestotug+Dostarlimab doublet in previously untreated, unresectable, locally advanced or metastatic PD-L1 high non-small cell lung cancer.</li>
<li>IO Biotech, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IOBT#NASDAQ">IOBT</a>) rose 18.2% to $0.8874 in pre-market trading. IO Biotech announced data from Phase 2 Basket trial of IO102-IO103, therapeutic cancer vaccine candidate, in combination with Merck&#8217;s Keytruda at the 2024 ESMO Congress.</li>
<li>Yunji Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YJ#NASDAQ">YJ</a>) gained 14.3% to $2.48 in pre-market trading after gaining 12% on Friday.</li>
<li>Adagene Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADAG#NASDAQ">ADAG</a>) shares rose 13.7% to $ 3.97 in pre-market trading. Adagene announced new ADG126 clinical data from ongoing Phase 1b/2 trial of SAFEbody Plus Keytruda Combo Presented at the ESMO Congress.</li>
<li>Entero Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTO#NASDAQ">ENTO</a>) gained 9% to $0.38 in pre-market trading after gaining around 6% on Friday.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Rafael Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RFL#NYSE">RFL</a>) fell 40.1% to $1.00 in pre-market trading after gaining 9% on Friday.</li>
<li>SMX (Security Matters) Public Limited Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMX#NASDAQ">SMX</a>) shares dipped 21.8% to $4.65 in pre-market trading after surging 143% on Friday.</li>
<li>Presidio Property Trust, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SQFT#NASDAQ">SQFT</a>) fell 20.4% to $0.55 in pre-market trading.</li>
<li>Psyence Biomedical Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) shares fell 16.7% to $0.13 in pre-market trading. Psyence Biomedical announced the receipt of staff delisting determination from Nasdaq.</li>
<li>Edgio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EGIO#NASDAQ">EGIO</a>) shares declined 14.7% to $1.33 in pre-market trading after dipping 27% on Friday.</li>
<li>Universe Pharmaceuticals INC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPC#NASDAQ">UPC</a>) shares fell 11.6% to $0.48 in pre-market trading after dipping around 67% on Friday.</li>
<li>Protagenic Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTIX#NASDAQ">PTIX</a>) shares fell 11.4% to $0.7001 in pre-market trading after declining 9% on Friday.</li>
<li>Purple Biotech Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PPBT#NASDAQ">PPBT</a>) shares declined 11.2% to $0.3438 in pre-market trading after gaining 7% on Friday.</li>
<li>LeddarTech Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LDTC#NASDAQ">LDTC</a>) fell 9.4% to $0.4001 in today's pre-market trading.</li>
<li>Guardant Health, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GH#NASDAQ">GH</a>) declined 8.2% to $24.60 in pre-market trading after gaining around 5% on Friday.</li>
</ul>
<a href="https://www.benzinga.com/markets/24/09/40860420/jim-cramer-hold-on-to-builders-firstsource-heres-the-problem-with-viking-therapeutics">Now Read This: </a>
<ul>
<li><a href="https://www.benzinga.com/markets/24/09/40860420/jim-cramer-hold-on-to-builders-firstsource-heres-the-problem-with-viking-therapeutics">Jim Cramer: &#8216;Hold On&#8217; To Builders FirstSource, &#8216;Here&#8217;s The Problem&#8217; With Viking Therapeutics</a></li>
</ul>

Psyence Biomedical Receives Nasdaq Delisting Determination; Company Has Not Regained Compliance

Psyence Biomedical Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) announced a major milestone on Monday with the initiation of the first clinical trial site in Australia for its Phase IIb study on nature-derived <a href="https://www.benzinga.com/topic/psilocybin">psilocybin</a> as a potential treatment for Adjustment Disorder in patients receiving palliative care. This development marks a key step toward advancing <a href="https://www.benzinga.com/topic/psychedelic-assisted-therapies">psychedelic-based treatments</a> in the healthcare industry.
The trial, conducted in partnership with Fluence, a leader in psychedelic therapy research, and iNGENū CRO Pty Ltd, a renowned Australian clinical research organization, aims to explore the efficacy of Psyence's naturally sourced psilocybin drug, <a href="https://www.benzinga.com/markets/cannabis/23/03/31444645/psychedelic-research-expands-in-australia-with-palliative-care-partnership-new-mdma-analog-portf">PEX010</a>. As the company <a href="https://www.globenewswire.com/news-release/2024/09/09/2942714/0/en/Psyence-Biomed-Announces-Initiation-of-First-Trial-Site-in-Australia-for-its-Phase-IIb-Study-of-Nature-Derived-Psilocybin-as-a-Potential-Treatment-for-Adjustment-Disorder-in-Pallia.html">stated</a>, patient screening is set to begin immediately, with the first subject expected to be randomized in October.
<h3 class="wp-block-heading">A Critical Advancement For Psychedelic Therapeutics</h3>
Dr. Clive Ward-Able, medical director of Psyence Biomedical, expressed enthusiasm about the trial's progression. &#8220;The imminent activation of the first trial site and patient screening for this trial represents a significant milestone for our company and a positive step forward for the advancement of psychedelic-based therapeutics generally,&#8221; he said. He emphasized that data from the study, expected in the second half of 2025, could pave the way for a pivotal Phase III clinical program.
The study will investigate the effects of psilocybin on patients suffering from Adjustment Disorder, particularly those dealing with life-limiting cancer diagnoses. The randomized, double-blind, placebo-controlled trial will evaluate two therapeutic doses of psilocybin (10mg and 25mg) against an active low-dose comparator (1mg) in conjunction with psychotherapy, enrolling 87 patients.
<h3 class="wp-block-heading">Promising Partnerships Driving Innovation</h3>
Veronika Simic, senior clinical project manager at iNGENū, highlighted the potential of psilocybin in addressing unmet mental health needs. &#8220;We believe psilocybin holds great promise as a treatment for a broad range of mental health conditions,&#8221; Simic stated. She also reaffirmed iNGENū's commitment to efficiently advancing the study in collaboration with Psyence Biomedical.
The <a href="https://www.benzinga.com/news/24/07/39966103/why-psyence-biomedical-pbm-stock-is-skyrocketing">export of PEX010 to Australia</a> earlier this year was a crucial preparatory step, and the trial site's activation signals significant progress toward exploring the therapeutic potential of naturally derived psilocybin.
Cover image made with AI

Psyence Biomedical files to sell 10.9M common shares for holders.

Psyence Biomedical files to sell 10.9M common shares for holders

Psyence Biomedical to not proceed with Clairvoyant acquisition

Psyence Biomedical (PBM) has released an update. Psyence Biomedical Ltd. has entered into a debt-for-equity exchange agreement with Newcourt SPAC S...

Psyence Biomedical Converts Debt to Equity

Psyence Biomedical (PBM) announced the recruitment of Perth, Australia-based Empax Center as the second trial site for Psyence's Biomed ongoing Pha...

Psyence recruits Empax Center as second trial site for Phase IIb trial

Psyence Group announced the closing of its previously announced disposal of its 11.13% stake in privately held PsyLabs to its NASDAQ-listed associa...

Psyence Group closes disposal of stake in PsyLabs

In this week's "Rising High," The Fly's recurring series focused on cannabis and psychedelic stock news, The Fly looks back on earnings, an acquisi...

Rising High: Compass Pathways reports Q3 earnings

Psyence Biomedical (PBM) has released an update. Psyence Biomedical has successfully closed its acquisition of Psyence Group's stake in PsyLabs, en...

Psyence Biomedical Acquires Stake in PsyLabs

Psyence Biomedical fell on 75-to-1 share consolidation and Nasdaq delisting notice

Psyence Biomedical (PBM) has released an update. Psyence Biomedical announced key outcomes from its annual meeting, including the approval of a 75-...

Psyence Biomedical Announces Share Consolidation Strategy

CANN

CRON

CVSI

FFNTF

GTBIF

SHFS

SKYE

TCNNF

TLRY

VREOF

Financing

Psyence Biomed Announces the Signing of a Conditional Binding Term Sheet for the Acquisition of Psilocybin-Based Drug Developer Clairvoyant

Psyence Biomed Announces Initiation of First Trial Site in Australia for its Phase IIb Study of Nature Derived Psilocybin as a Potential Treatment for Adjustment Disorder in Palliative Care

Psyence Biomedical Ltd. Announces Receipt of Staff Delisting Determination from Nasdaq

Psyence Biomed Issues Shareholder Update Recapping Recent Progress and Previewing Key Upcoming Data Milestones

Psyence Biomed Enters into Agreement to Acquire Stake in PsyLabs

Psyence Biomed Provides Update on Previously Announced Acquisition of Clairvoyant

Psyence Biomed Provides Progress Update on PsyLabs E.U. Good Manufacturing Practices (GMP) Certified Active Pharmaceutical Ingredient (API) Development

Psyence Biomed Announces Recruitment of Second Clinical Trial Site for Ongoing Phase IIb Clinical Trial of Nature-Derived Psilocybin for Adjustment Disorder in Palliative Care

Psyence Biomedical Announces Closing of Previously Announced Acquisition of Psyence Group's Stake in PsyLabs

Psyence Biomedical Announces Results from Annual and Special General Meeting, Share Consolidation and Receipt of Additional Staff Determination from Nasdaq

Comments

Psyence Biomedical

Psyence Biomedical (PBM) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga